State the pattern first: across six of biotech's most important companies, the 2026 filings read less like victory laps and more like risk-management memos. Lined up side by side — which the EdgarBeast evidence index makes straightforward — the disclosures point the same direction, and three filings agreeing is a trend worth naming.
Start with the incretin leaders. Lilly's FY2025 10-K ties its growth to the uptake of Zepbound and the unapproved oral orforglipron and recalls years when demand outran supply. Novo's FY2025 20-F discloses that U.S. price negotiation now covers Ozempic, Rybelsus, and Wegovy. The two GLP-1 giants, between them, are flagging the two classic post-boom risks: execution and price.
Now the platform and franchise names. Moderna's FY2025 10-K shows R&D cut from $4.8 billion in 2023 to $3.1 billion in 2025 as cash sat near $2.6 billion — a company resizing to its means. Vertex's FY2025 10-K leans part of its outlook on the commercial success of its new non-opioid pain drug Journavx, a bet beyond its cystic-fibrosis base. Different situations, same posture: managing the next chapter, not banking the last one.
The two science-heavy disclosures complete the picture. Regeneron's FY2025 10-K states plainly that EYLEA and EYLEA HD face significant competition. CRISPR Therapeutics' FY2025 10-K discloses that Vertex has significant control over its lead Casgevy program. One concedes a commercial threat; the other concedes a control dependency. Neither hides it.
What ties these six together is not bad news — most of these companies are thriving. It is candor about constraint. The filings are where optimism meets the legal obligation to disclose risk, and in 2026 that collision produces a consistent message: the biotech boom is real and being actively managed against supply, price, cash, competition, and control.
The discipline for a reader is to treat that candor as signal. A press release tells you what a company hopes; the filing tells you what it must manage. Read six at once and the sector stops looking like a single euphoric story and starts looking like what it is — a set of powerful franchises, each navigating a specific, disclosed risk. That is the docket for 2026.